Effects of Fullerenol C60(OH)24 on Cytotoxicity Induced by Antitumor Drugs on Human Breast Carcinoma Cell Lines


Article Preview

The aims of this paper were to investigate cell growth activity of fullerenol C60(OH)24, its modulating effect on antitumor drug-induced cytotoxicity, and genotoxic influence of fullerenol at nanomolar concentrations. Human breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with fullerenol at concentrations from 0.9 to 3.9 µg/ml alone or simultaneously with antitumor drugs (doxorubicin, cisplatin, taxol, and tiazofurin; IC50 concentrations) for 2 hours. Growth inhibition was evaluated by colorimetric SRB assay after recovery period of 24, 48, and 96 hours. The genotoxic examination was performed using sister chromatid exchange test and micronucleus assay, at fullerenol concentration ranging from 1 to 5 µg/ml. The fullerenol alone mildly inhibits the growth of both cell lines. Simultaneous administration of fullerenol and antitumor drugs strongly suppressed antitumor drug-induced cytotoxicity. The rate of cytotoxicity inhibition depended on fullerenol concentration, type of antitumor drug and cell line. Protection against doxorubicin and cisplatin was more pronounced than against taxol and tiazofurin. Fullerenol was not found to be genotoxic to investigated cell lines.



Edited by:

Dragan P. Uskokovic, Slobodan K. Milonjic, Djan I. Rakovic




V. Kojić et al., "Effects of Fullerenol C60(OH)24 on Cytotoxicity Induced by Antitumor Drugs on Human Breast Carcinoma Cell Lines ", Materials Science Forum, Vol. 494, pp. 543-548, 2005

Online since:

September 2005




[1] H.W. Kroto, J.R. Heath, S.C. O'Brien, R.F. Curl, R.E. Smaliey, C60: Buckminsterfullerene, Nature (London) 318 (1985), p.162.

[2] A. Djordjevic, Chemical derivatisation of fullerene C60 and biological investigation (Zaduzbina Andrijevic, Beograd, 2002).

[3] C. Yu, J.B. Bhonsle, L.Y. Wang, J.G. Lin, B-J. Chen and L.Y. Chiang, Fullerene Science and Technology, Vol. 5 (1997), p.1407.

[4] S.C. Chuech, M.K. Lai, M.S. Lee L.Y. Chaing T.I. Ho and S.C. Chen, Transplantation ProCeedings, Vol. 31 (1999), p. (1976).

[5] H-S. Lai, W.J. Chen and L.Y. Chaing, World Journal of Surgery, Vol. 24 (2000), p.450.

[6] T. -H. Ueng, H. -W. Wang and L. Y. Chaing, Fullerene Science and Technology, Vol. 7 (1999), p.681.

[7] G. Bogdanović, M. Vojinović-Miloradov, V. Kojić, A. Đorđević, J. Čanadi, Đ. Koruga, V.V. Baltić and D. Tabš, Archive of Oncology, 5/3 (1997), p.147.

[8] D. Jakimov, G. Bogdanovic, M. Baltić, S. Turšijan, L. Aleksić, A. Đorđević, J. Mrđanović and M. Vojinović-Miloradov, Advances in simulation, systems theory and systems engineering, (WSEAS Press (2002), pp.117-122).

[9] G. Bogdanovic, V. Kojic, A. Đorđević, J. Čanadanovic-Brunet, M. Vojinović-Miloradov and V.V. Baltić, Toxicology in vitro, (2004), p.629.

DOI: https://doi.org/10.1016/j.tiv.2004.02.010

[10] L.P. Zakharenko, I.K. Zakharov, E.A. Vasyunina, T.V. Karamysheva, A.M. Danilenko and A.A. Nikiforov, Russian Journal of Genetics, Vol. 33/3 (1997), p.327.

[11] G. Bogdanović, J. Raletić-Savić, N. Marković, Arch. Oncol., Vol. 2 (1994), p.181.

[12] A. Djordjevic, M. Vojinovic-Miloradov, N. Petranovic, A. Devecerski, D. Lazar and B. Ribar, Fullerene Sciences and Technology, Vol. 6 (1998), p.689.

DOI: https://doi.org/10.1080/10641229809350229

[13] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. i Bokesch, S. Kenney and M. R. Boyd, Drug Screening. Articles, Vol. 82 (1990), p.1107.

DOI: https://doi.org/10.1093/jnci/82.13.1107

[14] Cytogenetic analysis for radiation dose assessment - a manual (Technical reports series No. 405, International Atomic Energy Agency, Vienna, 2001).

[15] Guide to short-term tests for detecting mutagenic and carcinogenic chemicals. Prepared for the International Programme on Chemical Safety (IPCS) by the International Commission for Protection Against Mutagens and Carcinogens, World Health Organisation, Geneva, (1985).

DOI: https://doi.org/10.1177/096032718600500622

[16] J.M. Barch, The ACT cytogenetic laboratory manual - 2nd edition (Raven Press, New York, 1991).

[17] R.S. Verma, A. Babu, Human chromosomes: Principles and techniques - 2nd edition. (McGraw-Hill, Health professions division, New York, 1995).

[18] M Fenech, Drug Discovery Today, Vol. 7 No. 22 (2002), p.1128.

[19] T.V. De Vita, J.R.S. Hellman and A.S. Rosenberg, Cancer principles and practice of oncology (Philadelphia: Lippincott-Raven, 1997: 1-16, 375-512).

[20] G. Weber and N. Preida, Adv. Enzime Regul., Vol. 34 (1994), p.71.

[21] Q. Li, Y. Xiu, X. Zhang, R. Liu, Q. Du, X. Shun, S. Chen and W. Li, Nuclear Medicine and Biology, Vol. 29 (2002), p.707.

[22] C.M. Sayes, J.D. Fortner, W. Guo, D. Lyon, A.D. Boyd, K.D. Ausman, Y.J. Tao, B. Sitharaman, L.J. Wilson, J.B. Hughes, J.L. West and V.L. Colvin, Nano Letters Vol. 0 (2004), P. A-G.

DOI: https://doi.org/10.1021/nl0489586